HC Wainwright Issues Optimistic Estimate for LBRX Earnings

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of LB Pharmaceuticals in a note issued to investors on Monday, August 3rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.95) per share for the quarter, up from their previous estimate of ($0.97). HC Wainwright currently has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($3.51) EPS, Q1 2027 earnings at ($1.13) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.29) EPS and FY2027 earnings at ($4.87) EPS.

Several other research analysts have also commented on LBRX. Roth Capital reissued a “buy” rating and issued a $37.00 price objective on shares of LB Pharmaceuticals in a research note on Sunday, May 17th. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a research note on Friday, April 10th. They set a “buy” rating and a $36.00 target price on the stock. Wall Street Zen upgraded shares of LB Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Piper Sandler restated an “overweight” rating and issued a $78.00 price target on shares of LB Pharmaceuticals in a research note on Monday. Finally, Wolfe Research began coverage on LB Pharmaceuticals in a research report on Tuesday, July 7th. They set an “outperform” rating and a $45.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $45.12.

LB Pharmaceuticals Price Performance

Shares of NASDAQ:LBRX opened at $45.00 on Wednesday. The firm has a market capitalization of $1.29 billion and a PE ratio of -26.01. The firm’s 50-day moving average is $32.10 and its two-hundred day moving average is $28.05. LB Pharmaceuticals has a 1 year low of $13.36 and a 1 year high of $46.01.

LB Pharmaceuticals (NASDAQ:LBRX) last announced its earnings results on Tuesday, May 12th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08.

Institutional Trading of LB Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Stempoint Capital LP purchased a new position in LB Pharmaceuticals in the first quarter worth approximately $1,233,000. Janus Henderson Group PLC purchased a new stake in shares of LB Pharmaceuticals in the 1st quarter valued at approximately $1,613,000. Eversept Partners LP acquired a new stake in shares of LB Pharmaceuticals in the 1st quarter valued at $2,471,000. Spruce Street Capital LP lifted its position in shares of LB Pharmaceuticals by 36.9% during the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company’s stock worth $33,645,000 after purchasing an additional 370,566 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of LB Pharmaceuticals by 12.2% during the 1st quarter. Bank of New York Mellon Corp now owns 45,457 shares of the company’s stock worth $1,121,000 after purchasing an additional 4,940 shares during the last quarter.

About LB Pharmaceuticals

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.